NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Core Insights - NeoGenomics has launched PanTracer Pro, a new integrated testing approach aimed at improving the selection of therapies for patients with advanced-stage solid tumors by providing earlier biomarker insights and reducing diagnostic uncertainty [1][2] Group 1: Product Features - PanTracer Pro integrates comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing tailored to tumor type, allowing for a more streamlined testing process [1] - The turnaround time for PanTracer Pro tests is 8–10 days, facilitating timely treatment decisions in real-world clinical settings [1] - The product aims to identify clinically relevant biomarkers that may be overlooked in incomplete testing, thus supporting therapy selection and personalized treatment planning [1] Group 2: Market Context - As precision oncology evolves, clinicians are facing increased complexity in diagnostics and biomarker requirements, necessitating quicker treatment initiation often before complete molecular profiles are available [1] - The fragmented nature of current testing workflows can lead to delays in patient care, which PanTracer Pro seeks to address by providing a coordinated testing approach [1] Group 3: Company Overview - NeoGenomics, Inc. is a leading provider of oncology diagnostic solutions, specializing in cancer genetics testing and information services, with a comprehensive testing menu serving various stakeholders in the oncology field [1]